Daily injection of KBP/placebo for up to 28 days

Phase 1Terminated
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Type II Diabetes Mellitus

Conditions

Type II Diabetes Mellitus

Trial Timeline

Apr 17, 2018 โ†’ Dec 3, 2019

About Daily injection of KBP/placebo for up to 28 days

Daily injection of KBP/placebo for up to 28 days is a phase 1 stage product being developed by Eli Lilly for Type II Diabetes Mellitus. The current trial status is terminated. This product is registered under clinical trial identifier NCT03907202. Target conditions include Type II Diabetes Mellitus.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03907202Phase 1Terminated